Stock Scorer

Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics, Inc. reported revenue of 481M USD for the quarter ending 30 June 2026, up 47.7% from 325.7M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 481M +47.7%
Gross Profit Q4 '20 · ending 31 December 2020 6.2M +2.9%
Operating Income Q2 '26 · ending 30 June 2026 287.7M +103.2%
Net Income Q2 '26 · ending 30 June 2026 229.9M +94.7%
Cost of Revenue Q2 '26 · ending 30 June 2026 79.2M +70.8%
Operating Cash Flow Q2 '26 · ending 30 June 2026 240.9M +141.6%
Free Cash Flow Q2 '26 · ending 30 June 2026 236.7M +141.2%
Shares Outstanding Q2 '26 · ending 30 June 2026 121.2M -4.3%
EPS Q3 '25 · ending 30 September 2025 4.75 +57.3%

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 1.4B469M316.9M644.6M
20242024-12-31 1B551.5M444.1M468.4M
20232023-12-31 829.3M337.6M281.6M373.3M
20222022-12-31 660.1M267.5M202.1M235.3M
20212021-12-31 443.3M275.9M402.7M298M
20202020-12-31 267.6M144.3M129.1M53M
20192019-12-31 196M-67.6M-72.2M-89.5M
20182018-12-31 151.9M-69.3M-80.3M-54.2M
20172017-12-31 316.6M81M63M132.7M
20162016-12-31 146.7M-83.2M-103M-53.5M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-30481M
Q1 '262026-03-31376.7M
Q4 '252025-12-31451.8M
Q3 '252025-09-30354.3M
Q2 '252025-06-30325.7M
Q1 '252025-03-31264.9M
Q4 '242024-12-31298M
Q3 '242024-09-30290.1M
Q2 '242024-06-30231.4M
Q1 '242024-03-31195.9M
Q4 '232023-12-31230M
Q3 '232023-09-30216M
Q2 '232023-06-30221M
Q1 '232023-03-31162.1M
Q4 '222022-12-31181.5M
Q3 '222022-09-30209M
Q2 '222022-06-30152.4M
Q1 '222022-03-31117.3M
Q4 '212021-12-31102M
Q3 '212021-09-30115.8M

Gross Profit Quarterly

PeriodEndingGross Profit
Q4 '202020-12-316.2M
Q3 '202020-09-303.5M
Q2 '202020-06-30597K
Q1 '202020-03-312.4M
Q4 '192019-12-316M
Q3 '192019-09-306.9M
Q2 '192019-06-303.9M
Q1 '192019-03-313.7M
Q4 '182018-12-315.1M
Q3 '182018-09-305.6M
Q2 '182018-06-303.6M
Q1 '182018-03-313.7M
Q4 '172017-12-315.1M
Q3 '172017-09-305.3M
Q2 '172017-06-305M
Q1 '172017-03-313.9M
Q4 '162016-12-315.4M
Q3 '162016-09-304.2M
Q2 '162016-06-305.4M
Q1 '162016-03-315.2M

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30287.7M
Q1 '262026-03-31184.5M
Q3 '252025-09-30217.9M
Q2 '252025-06-30202.4M
Q1 '252025-03-31141.5M
Q4 '242024-12-31175.5M
Q3 '242024-09-30163.2M
Q2 '242024-06-30117.2M
Q1 '242024-03-3195.5M
Q4 '232023-12-31101M
Q3 '232023-09-3088.3M
Q2 '232023-06-3094.5M
Q1 '232023-03-3153.8M
Q4 '222022-12-3174.5M
Q3 '222022-09-3083.3M
Q2 '222022-06-3034.1M
Q1 '222022-03-3175.7M
Q4 '212021-12-3156.5M
Q3 '212021-09-3075.6M
Q2 '212021-06-3093M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30229.9M
Q1 '262026-03-31150M
Q3 '252025-09-30175.2M
Q2 '252025-06-30165.2M
Q1 '252025-03-31118.1M
Q4 '242024-12-31137M
Q3 '242024-09-30137M
Q2 '242024-06-3093.2M
Q1 '242024-03-3176.8M
Q4 '232023-12-3185.4M
Q3 '232023-09-3081.8M
Q2 '232023-06-3074.8M
Q1 '232023-03-3139.6M
Q4 '222022-12-3157.7M
Q3 '222022-09-3061.6M
Q2 '222022-06-3022.7M
Q1 '222022-03-3160.1M
Q4 '212021-12-3166.8M
Q3 '212021-09-30216.6M
Q2 '212021-06-3091.5M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q2 '262026-06-3079.2M
Q1 '262026-03-3179.2M
Q4 '252025-12-3178.8M
Q3 '252025-09-3055.2M
Q2 '252025-06-3046.4M
Q1 '252025-03-3148.4M
Q4 '242024-12-3142.1M
Q3 '242024-09-3049.4M
Q2 '242024-06-3039.6M
Q1 '242024-03-3128.3M
Q4 '232023-12-3152.3M
Q3 '232023-09-3054.8M
Q2 '232023-06-3050.1M
Q1 '232023-03-3135.2M
Q4 '222022-12-3142.1M
Q3 '222022-09-3047.3M
Q2 '222022-06-3033.9M
Q1 '222022-03-3115.9M
Q4 '212021-12-3121.6M
Q3 '212021-09-3018.6M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30240.9M
Q1 '262026-03-31180.1M
Q4 '252025-12-31219M
Q3 '252025-09-30178.6M
Q2 '252025-06-3099.7M
Q1 '252025-03-31154.2M
Q4 '242024-12-31178.5M
Q3 '242024-09-30115.4M
Q2 '242024-06-3055.8M
Q1 '242024-03-31129.4M
Q4 '232023-12-31102.4M
Q3 '232023-09-30132.4M
Q2 '232023-06-3066.8M
Q1 '232023-03-3187M
Q4 '222022-12-3182.5M
Q3 '222022-09-3069.6M
Q2 '222022-06-3040.2M
Q1 '222022-03-3147.8M
Q4 '212021-12-3182.5M
Q3 '212021-09-30121.7M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30236.7M
Q1 '262026-03-31176.3M
Q4 '252025-12-31217.6M
Q3 '252025-09-30175.6M
Q2 '252025-06-3098.1M
Q1 '252025-03-31153.3M
Q4 '242024-12-31175.4M
Q3 '242024-09-30113.9M
Q2 '242024-06-3053.2M
Q1 '242024-03-31125.9M
Q4 '232023-12-3199.8M
Q3 '232023-09-30129.5M
Q2 '232023-06-3065.2M
Q1 '232023-03-3175.6M
Q4 '222022-12-3180.1M
Q3 '222022-09-3068.6M
Q2 '222022-06-3039.3M
Q1 '222022-03-3147.3M
Q4 '212021-12-3182.4M
Q3 '212021-09-30121.2M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30121.2M
Q1 '262026-03-31122.9M
Q3 '252025-09-30122.3M
Q2 '252025-06-30124.2M
Q1 '252025-03-31126.6M
Q3 '242024-09-30130.1M
Q2 '242024-06-30129.2M
Q1 '242024-03-31128.9M
Q3 '232023-09-30134.1M
Q2 '232023-06-30133.5M
Q1 '232023-03-31137.9M
Q3 '222022-09-30139.4M
Q2 '222022-06-30142.2M
Q1 '222022-03-31141.3M
Q3 '212021-09-30146.7M
Q2 '212021-06-30147.6M
Q1 '212021-03-31148.5M
Q4 '202020-12-31145.1M
Q3 '202020-09-30142.1M
Q2 '202020-06-30138.1M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q3 '252025-09-304.75
Q2 '252025-06-304.37
Q1 '252025-03-313.76
Q4 '242024-12-313.43
Q3 '242024-09-303.02
Q2 '242024-06-302.58
Q1 '242024-03-312.42
Q4 '232023-12-312.11
Q3 '232023-09-301.88
Q2 '232023-06-301.71
Q1 '232023-03-311.31
Q4 '222022-12-311.45
Q3 '222022-09-301.49
Q2 '222022-06-302.53
Q1 '222022-03-312.99
Q4 '212021-12-312.75
Q3 '212021-09-302.79
Q2 '212021-06-301.56
Q1 '212021-03-311.13
Q4 '202020-12-310.90